Miliary Tuberculosis in Immunocompromised Patient Induced by Imatinib and Steroid
DOI:
https://doi.org/10.25077/jka.v10i3.1821Abstract
Miliary tuberculosis occurs due to the hematogenous spread of Mycobacterium Tuberculosis from the primary complex.  The use of steroid and cytotoxic drugs increases the incidence of miliary tuberculosis.  Typical manifestations of miliary tuberculosis is snowstorm appearance seen on chest x-ray and evidence of tuberculosis microorganism from the microbiological examination.  It has been reported a 33 years old male patient was admitted to the hospital due to breathlessness, chronic coughing, fever, anorexia, weight loss and night sweating with a "damp shadow sign".  Due to chronic myelogenous leukemia and autoimmune hemolytic anemia, the patient is known under imatinib and steroid therapy.  There was no specific sign found from the physical examination.  Chest x-ray showed snowstorm appearance.  The patient underwent GeneXpert MTB/RIF, with the result low MTB detected.  The patient was treated with a 2(HRZE)/4(HR) tuberculosis drugs regimen.  Imatinib and steroid therapy was discontinued. 2-4 weeks of steroid usage with a daily dose equivalent to prednisone 15 mg increases the risk of activating a latent tuberculosis infection.  Imatinib affects the response of T cells to Mycobacterium, thereby triggering tuberculosis reactivation.  In this case, the diagnosis has been made from typical manifestations of tuberculosis, snowstorm appearance from the chest x-ray, and low MTB detected from GeneXpert MTB/RIF.  It has been recommended to detect latent tuberculosis infection before using steroid and cytotoxic drugs.
Keywords:  imatinib, miliary tuberculosis, steroid
Downloads
Published
Versions
- 2025-03-21 (2)
- 2022-01-27 (1)
How to Cite
Issue
Section
License
Copyright (c) 2022 Randa Fermada, Fauzar Fauzar, Roza Kurniati, Irza Wahid

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors retain copyright and grant the Jurnal Kesehatan Andalas right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike (CC BY-SA 4.0) license that allows others to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) the work for any purpose, even commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Kesehatan Andalas.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Kesehatan Andalas.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).










